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Summary
 
One hypothesis for the etiology of central nervous system (CNS) autoimmune disease is that
infection by a virus sharing antigenic epitopes with CNS antigens (molecular mimicry) elicits a
virus-specific immune response that also recognizes self-epitopes. To address this hypothesis,
transgenic mice were generated that express the nucleoprotein or glycoprotein of lymphocytic
choriomeningitis virus (LCMV) as self in oligodendrocytes. Intraperitoneal infection with
LCMV strain Armstrong led to infection of tissues in the periphery but not the CNS, and the
virus was cleared within 7–14 d. After clearance, a chronic inflammation of the CNS resulted,
accompanied by upregulation of CNS expression of MHC class I and II molecules. A second
LCMV infection led to enhanced CNS pathology, characterized by loss of myelin and clinical
motor dysfunction. Disease enhancement also occurred after a second infection with unrelated
viruses that cross-activated LCMV-specific memory T cells. These findings indicate that
chronic CNS autoimmune disease may be induced by infection with a virus sharing epitopes
with a protein expressed in oligodendrocytes and this disease may be enhanced by a second in-
fection with the same or an unrelated virus. These results may explain the association of several
different viruses with some human autoimmune diseases.
 
T
 
he concept of molecular mimicry has been proposed
for the etiology of autoimmune diseases (1–5). In mo-
lecular mimicry, a pathogen such as a virus shares peptide
sequences or conformations with a host protein. The im-
mune response to the viral infection results in a cross-reac-
tive autoimmune attack against a target tissue expressing
the mimicked protein. To date, molecular mimicry has
been suggested to play a role in the pathogenesis of several
human diseases, including insulin-dependent diabetes mellitus
(6), ankylosing spondylitis (7), Guillain–Barre syndrome
(8), primary biliary cirrhosis (9), and multiple sclerosis
(MS)
 
1
 
 (10–12), but has yet to be conclusively shown to be
the initiating factor of these autoimmune diseases. 
We have developed a transgenic mouse model to exam-
ine whether molecular mimicry between a virus and a pro-
tein expressed in oligodendrocytes can lead to central ner-
vous system (CNS) autoimmune disease. In this model
system, transgenic mice were generated that express a viral
protein exclusively in oligodendrocytes. Adult transgenic
mice were then infected with a virus that encoded the same
gene, did not infect the CNS, and was quickly cleared by
the host immune response. These mice were examined to
determine whether the virus-induced immune response
could result in an autoimmune attack against the viral
transgene product expressed in oligodendrocytes, leading
to CNS disease.
The nucleoprotein (NP) and glycoprotein (GP) of lym-
phocytic choriomeningitis virus (LCMV) were selected as
transgenes and cloned under the control of the myelin basic
protein (MBP) promoter. These viral genes were chosen
for the following reasons. First, the immune response to
LCMV has been well characterized (13, 14). After periph-
eral (i.p.) infection of mice with LCMV strain Armstrong,
a vigorous CD8
 
1
 
 CTL response is generated that clears the
virus from all tissues by 7–10 d after infection (13, 14).
CTL epitopes of LCMV have been defined on several
MHC backgrounds, including H-2
 
d
 
 and H-2
 
b
 
 (15, 16).
Second, i.p. infection of immunocompetent mice with
LCMV results in the infection of many tissues but not cells
of the CNS. Thus, in this system it is possible to test
whether the generation of an immune response against a
 
1
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viral infection in the periphery can result in immune attack
against CNS components.
In this report, we present the results of peripheral infec-
tion of these transgenic mice by LCMV. We found that the
LCMV infection was efficiently cleared, but a chronic CNS
autoimmune disease developed and was enhanced by a sec-
ond infection with LCMV or with unrelated viruses that
stimulated LCMV-specific memory immune responses. This
disease was characterized by T cell inflammatory lesions in
the brain and spinal cord that included areas indicative of
myelin loss, marked upregulation of CNS expression of
MHC class I and class II molecules, and clinical motor dys-
function. This model establishes that an immune response
to a peripheral viral infection can recognize identical anti-
gens presented as self in the CNS, resulting in chronic
CNS autoimmune disease.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
The LCMV Armstrong NP cDNA
was prepared by BamHI digestion from plasmid pARMNP, which
contains the entire coding sequence of the NP. The full-length
cDNA of the LCMV Armstrong GP was obtained by RT-PCR
amplification of viral RNA. Total RNA was purified from the
brain of a mouse that had been persistently infected with LCMV
Armstrong since birth. cDNA was made using random hexamer
primers and murine Maloney leukemia virus reverse transcriptase
as described (17). PCR amplification of the viral GP was done us-
ing primers that hybridize to the 5
 
9
 
 and 3
 
9
 
 ends of the GP sequence:
primer 1, which hybridizes to bp 1–26, 5
 
9
 
-CCGGGGATC-
CTAGGCTTTTTGGATTG-3
 
9
 
; and primer 2, which hybrid-
izes to bp 1553–1585, 5
 
9
 
–GGGGATCCTGTTCTTCAGCGT-
CTTTTCCAGAC–3
 
9
 
. PCR was done using Taq Polymerase
(Perkin Elmer Cetus, Norwalk, CT) following reaction condi-
tions indicated by the manufacturer and performing 35 cycles at
95
 
8
 
C for 1 min, 60
 
8
 
C for 1 min, 72
 
8
 
C for 3 min. The 1575-bp
product was cloned into the TA vector system (Invitrogen, San
Diego, CA) and then digested with BamHI. The NP and GP
cDNAs were cloned into the BamHI site of pMBP001, which
contains sequences from 
 
2
 
1907 to 
 
1
 
36 of the MBP promoter,
followed by a polylinker region linked to a portion of the proteo-
lipid protein (PLP) gene as described (18). The PLP sequences
provided splice and polyadenylation signals and included PLP
exon 6, intron 6, and exon 7. Linear DNA fragments containing
the regulatory regions plus NP or GP sequences were obtained by
NotI digestion. The DNA was microinjected in The Scripps Re-
search Institute Transgenic Facility into BALB/cByJ 
 
3
 
 C57BL/6J
fertilized eggs. LCMV–NP transgenic mice were bred to BALB/
cByJ (H-2
 
d
 
) mice, and the LCMV–GP transgenic mice were bred
to C57BL/6J (H-2
 
b
 
) mice. MBP–
 
b
 
-galactosidase (
 
b
 
gal) trans-
genic mice (18) were bred to BALB/cByJ and C57BL/6J mice.
All nontransgenic breeder mice were obtained from the breeding
colony at The Scripps Research Institute (La Jolla, CA).
 
DNA and RNA Analyses.
 
Transgenic founders were identi-
fied by hybridization of NP- or GP-specific 
 
32
 
P-labeled DNA
probes (19) to slot-blots containing samples of DNA extracted
from tail biopsies. Relative transgene copy numbers were deter-
mined by slot-blot hybridization as compared with known stan-
dards of gene copy number. Mice were characterized for RNA
expression by RT-PCR on total RNA isolated as described (17),
using primers that hybridize within the transgene and a primer
that hybridizes within PLP exon 7. RT-PCR products corre-
sponding to correctly spliced NP transgenes were 510 bp (NP)
and 780 bp (GP). RNase protection assays for cytokine mRNA
expression were done on 2–4 mice using 15 
 
m
 
g of purified total
brain RNA or 1 
 
m
 
g of poly-(A)
 
1
 
 mRNA as described (20, 21).
The relative amounts of cytokine RNA were quantitated by us-
ing the Series 400 PhosphorImager and ImageQuant software
(Molecular Dynamics, Sunnyvale, CA). Imager units (PI units)
were normalized to equivalence based on values for rpL32 tran-
scripts, which encode the L32 ribosomal protein (20, 22).
 
Virus Stocks and Infections of Mice.
 
LCMV Armstrong 53b, which
is a triple plaque–purified isolate of ARM CA 1371 (23), was used.
The AN3739 strain of Pichinde virus (24) was used. LCMV and
Pichinde viruses were passaged in baby hamster kidney (BHK)
cells. Recombinant vaccinia viruses made from strain WR con-
taining either no LCMV products, or the LCMV NP gene (VV–
NP), were generated and passaged as described (25). Transgenic
positive and negative mice were infected at 6–10 wk of age i.p.
with 0.5–2 
 
3
 
 10
 
6
 
 PFU of LCMV. In double infection experi-
ments, 6–10 wk after primary infection, mice were injected i.p.
with 2 
 
3
 
 10
 
6
 
 PFU LCMV, 2 
 
3
 
 10
 
6
 
 PFU Pichinde virus, 3.5 
 
3
 
10
 
6
 
 PFU VV–NP, or 3.5 
 
3
 
 10
 
6
 
 PFU vaccinia virus (VV).
 
Immunohistochemical Staining of CNS Tissues.
 
Mice were anes-
thetized and perfused with 40 ml saline. Brains and spinal cord
were removed, covered with Tissue-Tec OCT (Miles Diagnos-
tics Division, Elkhart, IN), snap-frozen at 
 
2
 
80
 
8
 
C in isopentane,
and then stored at 
 
2
 
20
 
8
 
C. Immunohistochemistry was performed
on 10–12-
 
m
 
m cryostat sections that were fixed in 100% ethanol
for 15 min at 4
 
8
 
C and blocked with avidin and biotin (Vector
Laboratories, Burlingame, CA). Staining was done with the fol-
lowing primary antibodies: anti-CD8 (anti-Ly-2 and Ly-3, Phar-
Mingen, San Diego, CA), anti-CD4 (anti L3T4; PharMingen),
anti-H-2 monotypic antigen (MHC class I), anti-Ia antigen
(MHC class II), anti-B220 (Boehringer Mannheim, Indianapolis,
IN), and anti-F4/80 (Serotec, Oxford, England). The second an-
tibody was a biotinylated anti-mouse IgG and was used in con-
junction with the Vectastain Elite ABC (peroxidase) kit (Vector
Laboratories). Staining was detected using diaminobenzidine as a
chromagen. Sections were counterstained in Mayer’s hematoxy-
lin (Sigma, St. Louis, MO) and mounted in Aqua-Mount (Lerner
Laboratories, Pittsburgh, PA).
Immunofluorescence staining for confocal microscopy was
performed on similarly prepared, cut, and fixed cryostat brain sec-
tions. Sections were blocked with Superblock (ScyTek, Logan,
UT) and stained with primary antibodies; rat anti–mouse CD8, rat
anti–mouse F4/80, and mouse anti–rat myelin basic protein
(Boehringer Mannheim, Indianapolis, IN). Secondary fluorescent
antibodies used were Texas red-labeled horse anti–mouse IgG
and FITC-labeled rabbit anti–rat IgG (Vector Laboratories) and
the slides were mounted in Vectashield (Vector Laboratories).
Double-immunolabeled sections were examined with a BioRad
(MRC 600) laser scanning confocal microscope equipped with an
argon/krypton mixed gas laser.
 
Chromium Release CTL Assays.
 
51
 
Cr-release CTL assays were
performed as described (25). In brief, primary LCMV-specific
CTL were generated by i.p. inoculation of 5 
 
3
 
 10
 
5
 
 PFU of
LCMV. Secondary viral CTL assays were done by infecting
LCMV-immune mice with viruses as indicated. 7 d later the ani-
mals were killed and single cell suspensions were prepared from
each of the spleens. Target cells were BALB clone 7 (H-2
 
d
 
) and
MC57 (H-2
 
b
 
) fibroblasts cell lines that were either uninfected or
infected 48 h before the assay with LCMV or 12 h before with
VV recombinants. The effector cells were plated with the target 
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cells at E/T ratios of 50:1 and 25:1 and incubated at 37
 
8
 
C for 5 h.
Effectors were always tested on both MHC-matched and MHC-
mismatched targets. The supernatants were harvested, and re-
leased 
 
51
 
Cr was measured in a 
 
g
 
-counter. The specific 
 
51
 
Cr release
was calculated by the following formula: ([experimental release 
 
2
 
spontaneous release] / [maximum release 
 
2
 
 spontaneous release])
 
3
 
 100. Each variable was tested in triplicate wells, and the vari-
ance among triplicates was within 10%.
 
Clinical Observations.
 
Mice were observed for signs such as
weight loss, ruffled fur, and ability to walk on a narrow stick (1 cm
diam). Mice were tested for balancing and motor coordination on
a rotating rod apparatus (rotorod) (26, 27). Age-matched LCMV-
infected transgenic positive and negative mice were placed onto
three separated compartments on the rod, which was then rotated
at a constant speed of 36 rpm. The length of time the mice re-
mained on the rod was recorded, with the test ending at a 3-min
maximum time on the rod. Each mouse was tested in three trials
separated by 1-min rest intervals.
 
Results
 
Generation of Transgenic Mice.
 
The cDNAs of the LCMV
NP and GP genes were cloned behind the MBP promoter
to direct expression to CNS oligodendrocytes as indicated
in Fig. 1 
 
A.
 
 This MBP promoter vector had previously
been shown to drive expression of a transgene specifically
in CNS oligodendrocytes in transgenic mice (18). Eight
founders were identified carrying the LCMV–NP con-
struct, and seven MBP–GP carriers were identified. Be-
cause greater than 97% of the LCMV-specific CTL re-
sponse on the H-2
 
d
 
 background is to an epitope in NP (16),
 
the MBP–NP mice were bred to BALB/cByJ (H-2
 
d
 
) mice
to maximize the proportion of NP-reactive CTL after
LCMV infection. Likewise, because the majority of LCMV-
specific CTL react with two epitopes in GP on the H-2
 
b
 
background (25), the MBP–GP mice were bred to C57BL/6
(H-2
 
b
 
) mice.
Tissue specific expression of the transgenes was demon-
strated by RT-PCR (Fig. 1 
 
B
 
). Oligonucleotide primers
were designed to take advantage of the PLP intron within
the vector. By amplifying a product across the intron as
shown in Fig. 1 
 
A
 
, spliced mRNA could be distinguished
from both unspliced mRNA as well as contaminating ge-
nomic DNA. RT-PCR product that corresponded in size
to correctly spliced RNA message was identified in the
brains of 7 out of 8 MBP–NP lines and in 7 out of 7 MBP–
GP lines. An RT-PCR survey of RNA from various or-
gans did not detect transgene-specific message in the liver,
kidney, spleen, pancreas, lung, heart, or sciatic nerve.
However, 
 
z
 
25% of the lines showed spliced RNA trans-
gene expression in the thymus. Two MBP–NP (5 and 60)
and two MBP-GP (36 and 46) lines with only CNS ex-
pression of the transgenes were chosen for further study
(Fig. 1, 
 
B
 
 and 
 
C
 
) and bred to the F4 level to BALB/c and
C57BL/6J mice, respectively. Immunohistochemical ap-
proaches (in situ immunohistochemistry and Western blot)
were undertaken to identify the transgene products in brain
tissue; however, these attempts were unsuccessful. Protein
expression in the MBP–NP and –GP mice is likely below
the level of sensitivity of antibody detection. Previous at-
tempts at identifying LCMV gene products expressed as a
Figure 1. Summary of MBP–NP and –GP transgenic mouse lines. (A)
pMBP001 contains 1.9 kb of the MBP gene promoter/enhancer se-
quences, and polyadenylation and splice signals from the PLP gene. The
LCMV NP and GP genes were cloned into the BamHI site of pMBP001
to give pMBP–NP and pMBP–GP. Expression of spliced mRNA in
transgenic mice was determined by RT-PCR using primers that hybrid-
ized within the transgene and the PLP exon 7 as indicated by arrows,
with the resulting RT-PCR products of 510 bp (MBP–NP) or 780 bp
(MBP–GP). (B) RNA from the brains (Brn) and spleens (Spl) of MBP–
NP and –GP transgenic mice was subjected to RT-PCR as described in
Materials and Methods to detect transgene-specific spliced RNA (see A). M,
molecular weight markers. (C) The transgenic mouse lines studied are
listed with the relative copy number of the transgene and the results of
RT-PCR transgene mRNA studies. 
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transgene of the rat insulin promoter in the 
 
b
 
 cells of the
Islets of Langerhans had also failed (19). However, these
transgenic mice were subsequently shown to express the
transgene as shown by CTL recognition of pancreatic 
 
b
 
 cells,
T cell recognition being at least two logs more sensitive
than antibody recognition (28, 29).
MBP–NP and –GP mice from all lines were observed
for up to 1 yr of age. None of the mice studied showed any
signs of clinical disease due to the consequences of brain-
specific expression of these viral genes. Additionally, histo-
logical examinations of CNS tissue taken at various ages did
not detect any abnormalities.
 
Characterization of the Immune Response to LCMV in Trans-
genic Mice.
 
This model requires the transgenic mice to
mount an immune response against the transgene, which is
a self-protein. Therefore, the first question addressed was
whether the transgenic mice were immunologically re-
sponsive to the transgene (self) products. The ability of the
MBP–LCMV transgenic mice to generate both anti-viral
(self) CTL and antibodies was assessed. CTL responses of the
transgenic mice were measured in 
 
51
 
Cr release assays using
splenic lymphocytes harvested 7 d after infection with LCMV.
Transgenic and nontransgenic mice from all four transgenic
MBP–NP and –GP lines were able to lyse MHC-matched
target cells infected with LCMV (Table 1). In addition,
BALB clone 7 (H-2
 
d
 
) target cells infected with a recombi-
nant VV expressing the NP from LCMV (VV–NP) were
lysed by lymphocytes from MBP–NP transgenic positive
and negative mice. Likewise, MC57 (H-2
 
b
 
) target cells in-
fected with a recombinant vaccinia virus expressing the GP
from LCMV (VV–GP) were effectively lysed by lympho-
cytes from MBP–GP transgenic positive and negative mice.
The ability of transgenic mice to mount anti-LCMV anti-
body responses was evaluated using an ELISA assay with
gradient-purified LCMV. At 2 mo after infection with
LCMV, MBP–NP and –GP transgenic positive and nega-
tive mice showed good antibody responses (antibody titers
 
.
 
10
 
5
 
; data not shown). Thus, the transgenic positive mice
generated LCMV-specific humoral and cellular immune
responses equivalent to transgenic negative mice, indicating
they were able to mount immune responses to the viral
self-proteins expressed as transgenes.
 
Effects of LCMV Infection of Transgenic Mice.
 
Transgenic
positive and negative mice from the two MBP–NP and
two MBP–GP lines (Fig. 1 
 
C
 
), bred to the F2–F4 level,
were infected peripherally with LCMV. After i.p. infection
of immunocompetent mice with LCMV, viral replication
occurs in many tissues and cell types, but not within the
CNS (14, 30). This was confirmed by in situ hybridization
studies using LCMV-specific riboprobes after i.p. infection
of transgenic mice (data not shown). Clearance of LCMV
in BALB/c and C57BL/6 mice normally occurs within
7–14 d after infection and is mediated by a vigorous CD8
 
1
 
CTL response (13, 14, 31). When assessed by plaque assays
of serum samples, transgenic positive mice cleared virus
with the same kinetics as transgenic negative mice.
To determine whether lymphocytic infiltration of the
CNS occurred after peripheral infection with LCMV,
transgenic positive and negative mice were killed at various
times postinfection and sagittal brain sections were stained
with antibodies to the T cell surface markers CD4 and
CD8. Approximately 1,000 lymphocytes were observed
per sagittal section at 1 wk after infection in both transgenic
positive and negative mice. The majority of these lympho-
cytes were CD8
 
1
 
 and were found within the meninges and
ventricular linings of the brain. These cells were most likely
activated by the viral infection and were trafficking through
the CNS as a normal part of immune surveillance after acti-
vation in the periphery (32). By 2 wk after infection, fewer
meningeal infiltrating cells were observed in both trans-
genic positive and negative mice. By 3 wk after infection,
in nontransgenic mice less than 30 lymphocytes could be
found per sagittal section, and by 5 wk after infection less
than 5 lymphocytes were detected per section. In contrast,
 
Table 1.
 
MBP–NP and –GP Mice Are Able to Generate Transgene-specific CTL Capable of Lysing MHC-matched,
LCMV-infected Target Cells
 
Effectors
Targets
BALB (H-2
 
d
 
) MC57 (H-2
 
b
 
)
Uninf LCMV VV–NP Uninf LCMV VV–GP
MBP–NP (H-2
 
d
 
) MBP–GP (H-2
 
b
 
)
Line 5  TG
 
2,
 
3
 
*
 
52 37 Line 36 TG
 
2,
 
34 4 4 2
TG
 
1,
 
34 1 2 9 T G
 
1,
 
34 7 4 3
Line 60 TG
 
2,
 
3 43 24 Line 46 TG
 
2, 34 4 3 7
TG1, 33 4 1 7 T G 1, 33 9 3 8
* Values are the percentage of chromium released from MC57 or BALB target cells, with an effector/target ratio of 50:1. The data shown are the av-
erages of values from two mice per group.2375 Evans et al.
in transgenic positive mice, at 3 wk after infection about 150–
300 CD81 cells were found per section. These cells were
located in the brain parenchyma as well as the brain stem
and spinal cord, and perivascular cuffs were often observed.
In addition, CD41 cells were present and comprised 20%
of the infiltrating T cells. Brains of transgenic positive mice
taken at various times after infection were found to contain
this level of CD81 infiltrates as long as 1 yr after infection.
By 1 yr after infection, the numbers of CD41 staining cells
had risen to approximately half the number of CD81 stain-
ing cells per section. At 3 wk after infection, the infiltrating
cells did not localize to any particular area or location
within the brain. By 3 mo after infection, clusters of CD41
and CD81 cells were found predominantly within the
white matter regions of the CNS, including the corpus cal-
losum, internal capsule, fimbria hippocampus, brain stem,
and spinal cord (Fig. 2, A, B, F, G). Lymphocytes were iso-
lated from the brains of MBP–NP transgenic positive mice
3 wk after LCMV infection and tested in 51Cr-release CTL
assays after in vitro stimulation with LCMV. These lym-
phocytes were found to effectively lyse MHC-matched tar-
get cells infected with either LCMV or recombinant VV
expressing the LCMV NP (data not shown).
To assess whether expression of a foreign protein by oli-
godendrocytes alone was enough to alter the pattern of im-
mune surveillance in the CNS, transgenic mice expressing
b-gal (MBP–bgal) using the same MBP expression vector
(18) were infected with LCMV and followed over time.
The pattern of kinetics of immune cell infiltration in MBP–
bgal mice was identical to that observed for the nontrans-
genic mice. To test whether infection with other viruses could
result in chronic CNS infiltration, MBP–LCMV transgenic
positive mice were infected with vaccinia virus or Pichinde
virus and followed over time. Infection of MBP–NP and
MBP–GP mice by either of these viruses did not result in a
chronic immune infiltration of their CNS tissue, and the
pattern of immune surveillance was similar to that observed
in nontransgenic mice.
Consequences of Chronic Immune Cell Infiltration. To charac-
terize further the effects of the inflammatory cell infiltration
of the CNS of transgenic positive and negative mice after
LCMV infection, brain sections were stained with addi-
tional immunohistochemical markers. The presence of B
cells in the infiltrating population was examined using anti-
body to the B cell marker, B220. Insignificant numbers of
B2201 cells were observed in both transgenic positive and
negative mice. Antibody to F4/80, a cell surface marker
found on microglia, monocytes, and macrophages, revealed
an upregulation of this molecule in regions of infiltrating
T cells in transgenic positive mice (Fig. 2, C and H). Micro-
glial activation was observed as long as 1 yr after infection
in association with T cell infiltration. Antibodies to MHC
class I and II molecules were used to determine whether an
increase in these antigen presentation markers was observed
in response to the immune cell infiltration (Fig. 2, D, E, I, J).
In uninfected and LCMV-infected nontransgenic mice,
MHC class I antigen staining was limited to the lepto-
meninges, choroid plexus, and endothelial cells of blood
vessels. MHC class II staining was confined to a few macro-
phage-like cells in the interstitium of the choroid plexus.
Staining for MHC class I and class II molecules in the
brains of transgenic positive mice revealed that by 6 wk af-
ter infection there was an upregulation of both of these an-
tigens on CNS cells in the vicinity of the infiltrating T cells,
particularly pronounced in white matter regions. Antibody
to MHC class I detected a fine reticular staining pattern in
white matter regions, as well as staining many distinct cell
types including those with microglial, lymphocyte, and en-
dothelial cell morphology. Oligodendrocytes expressing
MHC class I were identified by laser scanning confocal mi-
croscopy by colocalizing antibody to 29,39-cyclic nucleotide
39-phosphodiesterase (CNP) with antibody to MHC class I
(Horwitz, M.S, C.F. Evans, and M.B.A. Oldstone, manu-
script submitted for publication). Anti-MHC class II anti-
bodies stained cells of different morphologies including
cells similar to microglia. This upregulation of MHC class I
and class II molecules was observed in association with in-
filtrating lymphocytes for at least 1 yr after infection with
LCMV. Light and confocal microscopic analyses of sagittal
brain sections stained with luxol fast blue or antibodies to
myelin basic protein and CD8 failed to reveal any areas of
myelin damage in the transgenic mice after a single LCMV
infection.
Following infection with LCMV, transgenic positive and
negative mice were observed for clinical phenotypes in-
cluding ruffled fur, weight loss, and ability to walk on a
narrow stick. In addition, mice were subjected to a test uti-
lizing a rotating rod apparatus (rotorod), which measured
their ability to maintain balance and motor function. By
approximately 3 mo after infection, 75% of the transgenic
positive mice appeared ruffled and experienced balance dif-
ficulties when walking on the stick. No significant differ-
ences were observed between transgenic and nontransgenic
animals with the rotorod test. By 3.5 mo after infection, 2
out of 40 transgenic positive mice experienced seizures,
and 1 out of 40 exhibited weight loss and ataxia.
These results indicate that infection of mice by a virus
that shares immune determinants with a protein expressed
in oligodendrocytes can induce a chronic inflammatory dis-
ease of the CNS associated with clinical abnormalities.
Enhancement of Autoimmune CNS Disease by Memory T Cell
Stimulation. Since memory T cells require fewer activa-
tion signals and are potentially more aggressive than pri-
mary responding lymphocytes, the influence of a second
viral infection on the immunohistochemical and clinical
abnormalities in transgenic positive mice was examined.
MBP–NP transgenic positive and negative mice previously
infected with LCMV were reinfected with LCMV or a VV
recombinant encoding the NP transgene (VV–NP) at 6 wk
after primary infection. Immunohistochemical analysis of the
CNS showed a three- to fivefold increase in CD81 lym-
phocytes in the transgenic positive mice at 4 wk after sec-
ond infection with either LCMV or VV–NP, as compared
with transgenic positive mice infected singly with LCMV
at the same time after primary infection (10 wk). Addition-
ally, a 10-fold increase in the number of CD41 T cells was2376 Virus-induced Central Nervous System Autoimmune Disease
Figure 2. Immunohistochem-
ical analyses of the brain stems of
LCMV-infected MBP–NP trans-
genic positive and negative mice.
At 12 wk after infection with
LCMV, sagittal sections of the
brain stem from an MBP–NP
transgenic positive mouse (A–E)
and a transgenic negative mouse
(F–J) were stained with antibodies
to CD8 (A and F), CD4 (B and
G), F4/80 (C and H), MHC class
I (D and I), and MHC class II (E
and J) as described in Materials and
Methods. Bar, 100 mm; original
magnification,  3200.2377 Evans et al.
detected compared with the number of cells observed after
a single infection. The ratio of CD81 to CD41 cells in the
doubly infected mice was 2:1 (Fig. 3, A and B). The infil-
trating cells in the doubly infected transgenic mice were
found predominantly within white matter structures of the
brain, and perivascular cuffs were observed. Coinciding
with these increased levels of T cell infiltration, enhanced
areas of F4/80 staining were observed (Fig. 3, C and D). In
addition, an upregulation of the astrocyte marker glial fibril-
lary acidic protein (GFAP) was observed. A marked in-
crease in the expression of both MHC class I and II mark-
ers was observed in areas rich in myelin and coinciding
Figure 3. Immunohistochemical
analyses of the brains of LCMV-
infected MBP–NP mice reinfected
with LCMV 6 wk after the pri-
mary infection. MBP–NP trans-
genic positive and negative mice
were infected with LCMV; 6 wk
later they were given a second
LCMV infection, and then sacri-
ficed 4 wk after second infection.
Sagittal brain sections from trans-
genic positive (A, B, C, E, and G)
and transgenic negative (D, F, and
H) mice were stained with anti-
bodies to CD8 (A), CD4 (B), F4/
80 (C and D), MHC class I (E and
F), and MHC class II (G and H) as
described in Materials and Meth-
ods. (A and B) consecutive sec-
tions showing high power views of
infiltrating lymphocytes in white
matter within the internal capsule.
Bar, 125 mm; original magnifica-
tion, 3200. (C–H) Low power
views of the brain including the
internal capsule and fimbria hip-
pocampus. Bar, 375 mm; original
magnification, 340.2378 Virus-induced Central Nervous System Autoimmune Disease
with regions of T cell infiltration (Fig. 3, E–H). Oligoden-
drocytes were again identified by confocal microscopy as
expressing MHC class I.
Focal areas with high numbers of infiltrating T cells were
found in the parenchyma of the brain associated with mye-
lin tracts. These lesions of infiltrating lymphocytes spanned
several consecutive sections, ranged in size from 25–150 mm,
and as many as five lesions per sagittal section were found.
Immunohistochemical staining showed that they consisted
of both CD81 and CD41 T cells. Double immunofluores-
cent labeling of brain sections with antibody to CD8 and
MBP and subsequent confocal microscopic analysis re-
vealed a loss of MBP staining at the center of these lesions
(Fig. 4 A). Double labeling with antibodies to F4/80 and
MBP revealed the presence of activated macrophages/mi-
croglia around the lesions and colocalization of MBP within
these activated macrophages/microglia (Fig. 4, B–D).
To characterize the nature of the CNS-directed immune
response, RNA extracts from the brains of MBP–NP trans-
genic positive and negative mice undergoing the double
infection protocol were subjected to an RNase protection
assay using probes to a number of cytokines (20). Brains
from transgenic mice first infected with LCMV, second-
arily infected 6 wk later with either LCMV or VV–NP,
and sacrificed after another 4 wk, contained increased mes-
sage levels of the following cytokines when compared with
Figure 4. Characterization of T cell lesions by confocal microscopic analysis. An MBP–NP transgenic positive mouse was infected with LCMV, rein-
fected with LCMV at 6 wk after infection, and killed 12 wk after second infection. Cryocut brain sections were doubled immunofluorescently stained
and analyzed by laser scanning confocal microscopy as described in Materials and Methods. (A) shows double staining of T cell lesions in the cortex with
antibodies to CD81 T cells (green) and MBP (red). (B, C,and D) show a region of the cortex stained with antibodies to F4/80 (B, green), MBP (C, red),
and the merged view with both labels (D, areas of colocalization of MBP and F4/80 are presented in yellow [arrow]). Bar, 25 mm.
Figure 5. Expression of cytokines and measurement of clinical motor dysfunction in transgenic mice infected twice with LCMV. (A) mRNAs for var-
ious cytokines were detected by RNase protection assays using RNA isolated from mouse brains as described in Materials and Methods. Nontransgenic
(NTG) or transgenic (TG) mice were infected with LCMV, 6 wk later given a second LCMV infection, and sacrificed 4 wk later (n 5 2–4). PI units,
phosphoroimage units as defined in Materials and Methods. Values are plotted as mean 6 SE. (B) MBP–NP mice were infected with LCMV and 6 wk
later reinfected with LCMV. Four transgenic positive (open circles) and negative (closed circles) mice were tested for motor dysfunction on a rotorod appara-
tus in three consecutive trials as described in Materials and Methods. The time on the rotorod was measured, with a maximum of 180 s. The standard er-
ror is shown for all trials except the transgenic negative third trial, in which 3 out of 4 mice remained on the rod for the maximum time allowed.2379 Evans et al.
uninfected mice, or doubly infected nontransgenic mice:
IFN-g, TNF-a, TNF-b, IL-1a, IL-1b, and IL-12p40
(Fig. 5 A). No mRNAs for IL-2, IL-3, IL-4, IL-5, IL-6,
IL-10, or IL-13 were detected in transgenic positive or
negative brains. Nontransgenic mice showed minor in-
creases in the levels of TNF-a, TNF-b, and IL-1b message
at 4 wk after second infection. This was most likely the re-
sult of immune surveillance and trafficking after viral in-
duction of the memory immune response.
Following a second viral infection with LCMV or
VV–NP, transgenic positive and negative mice were tested
for motor impairment on the rotorod apparatus. As seen in
Fig. 5 B, transgenic negative mice performed significantly
better than the transgenic positive mice over three trials on
the rotorod. These differences in rotorod balancing indi-
cated motor coordination dysfunction in the doubly in-
fected transgenic mice (26, 27).
Secondary Infection by Unrelated Viruses Stimulates LCMV
Memory CTL and Enhances Autoimmune CNS Disease. To
determine whether enhanced disease following stimulation
of the LCMV memory response required that the second
restimulating virus encoded the transgene, transgenic mice
previously infected with LCMV were given a second infec-
tion with either VV, using a recombinant VV not encoding
any LCMV genes, or PV, an arenavirus distantly related to
LCMV but not sharing any of the defined LCMV CTL
epitopes. MBP–NP transgenic positive and negative mice
that had been infected with LCMV 6 wk previously were
infected with either VV or PV. 4–8 wk later, the mice
were killed and CNS tissues were examined. Stimulation of
the memory response by these unrelated viruses resulted in
enhanced pathology similar to that seen after a second in-
fection with LCMV. This included greater numbers of in-
filtrating lymphocytes, an increase in the ratio of CD41 to
CD81 lymphocytes, and a high preponderance of these in-
filtrates in white matter-rich areas (Fig. 6, A and B). Addi-
tionally, activation of microglia and astrocytes, as measured
by increased F4/80 and GFAP expression, were observed,
as well as increased upregulation of the antigen presentation
MHC class I and II molecules throughout the white matter
regions. Infiltrating lymphocytes formed lesions within the
white matter tracts of the CNS. These lesions showed a loss
of MBP staining accompanied by uptake of MBP by acti-
vated microglia/macrophages similar to that observed after
a second infection with LCMV.
To address whether infection of LCMV-immune mice
with VV or PV reactivated LCMV-specific CTL as has
been observed in C57BL/6 mice (33), BALB/c mice were
infected with LCMV; after 6 wk they were given a second
viral infection with VV or PV. In addition, these viruses
were also injected into BALB/c mice that had not received
the initial LCMV infection. At 5–7 d after infection,
splenic lymphocytes were isolated and tested in an in vitro
51Cr-release assay for LCMV-specific CTL activity. Al-
though primary VV- or PV- specific CTL did not recognize
LCMV-infected target cells, infection of LCMV-immune
BALB/c mice with either virus resulted in the activation of
LCMV-specific CTL memory cells capable of lysing MHC-
matched (Table 2) but not mismatched (data not shown)
LCMV-infected target cells. This indicated that infection
of LCMV-immune mice with a second virus not encoding
LCMV gene products activated LCMV-specific CTL.
Discussion
This study describes a transgenic mouse model in which
peripheral infection by a virus that shares immune epitopes
with a protein expressed in oligodendrocytes led to CNS
autoimmune disease. Without infecting the CNS, this virus
induced disease characterized by chronic inflammation of
the CNS and clinical motor dysfunction. This finding is
significant, since several recent reports have provided evi-
dence that molecular mimicry induced by a virus or other
pathogen may play a role in the etiology of human CNS
autoimmune diseases. For example, evidence for molecular
mimicry between viral proteins and human MBP was
found on the basis of structural similarities between an im-
munodominant MBP peptide and viral peptide sequences
Figure 6. Stimulation of in-
creased CNS immune infiltration
and activation of LCMV-memory
CTL by infection with a second
virus not encoding LCMV gene
products. An MBP–NP transgenic
positive mouse was infected with
LCMV followed by VV infection
6 wk later. After another 6 wk, the
mouse was sacrificed and increased
numbers of CD81 (A) and CD41
(B) cells compared with those ob-
served after a single LCMV infec-
tion were detected in the brain by
immunohistochemical staining as
described in Materials and Meth-
ods. Bar, 200 mm; original magni-
fication 3100.2380 Virus-induced Central Nervous System Autoimmune Disease
(10). Specific peptides from herpes simplex, adeno-, human
papilloma, Epstein–Barr, influenza, and reo-viruses were
able to activate human MBP-specific T cell clones that had
been established from peripheral blood lymphocytes of two
multiple sclerosis (MS) patients. A peptide from the bacte-
rium Pseudomonas aeruginosa was also able to activate one of
the MBP-specific T cell clones. Activation of the MBP-
specific T cell clones by as many as 3–4 different viral pep-
tides indicated that a single TCR could recognize peptides
from several unrelated sources, and this recognition re-
sulted in T cell activation. In other studies, T cell lines es-
tablished from MS patients were reactive to both MBP and
a sequence from the human respiratory coronavirus 229E
(11, 34). Additionally, molecular mimicry between human
transaldolase (TAL-H), which in the brain is expressed se-
lectively in oligodendrocytes, and human T cell lympho-
tropic virus type I/human immunodeficiency virus type 1 gag
proteins has also been described (12). TAL-H stimulated
proliferation of peripheral blood lymphocytes from patients
with MS, and in addition, autoantibodies to TAL-H were
detected in the serum and cerebrospinal fluid of these pa-
tients. Thus, molecular mimicry between viruses and oli-
godendrocyte proteins may be important in the etiology of
a human CNS autoimmune disease such as MS.
For an autoimmune T cell response to occur, self-reac-
tive T cells must escape thymic negative selection as well as
peripheral tolerance by clonal deletion or induction of an-
ergy. In this model, no evidence for T cell tolerance to the
viral (self) transgene products was obtained. Thymic ex-
pression of transgene mRNA was not detected by RT-
PCR, and CTL and antibody responses to the transgene
were similar to those observed in nontransgenic mice.
Since transgene product–specific CTL could be isolated
from the brains of transgenic mice following infection with
LCMV, this indicated that self-reactive T cells in the pe-
riphery were activated by the viral infection and trafficked
into the CNS where the transgene was expressed. T cells
reactive to MBP have been isolated from healthy individu-
als as well as MS patients (35). Therefore, it is possible that
infection by a virus sharing epitopes with a myelin compo-
nent such as MBP could result in activation of self-reactive
T cells that would cross the blood–brain barrier and recog-
nize oligodendrocytes presenting self-peptides. 
Mice expressing the LCMV NP or GP in their oligo-
dendrocytes developed CNS autoimmune disease after a
single infection with LCMV, and this disease was enhanced
after a second infection with LCMV. This enhancement
likely resulted from the activation of LCMV-specific memory
T cells that traveled into the CNS, where they encountered
transgene-expressing oligodendrocytes presenting LCMV pep-
tides in association with MHC class I molecules. Increased
levels of cytokines typically associated with activated CD81/
CD41 (Th1) cells were detected (IFN-g, TNF-a, and
TNF-b), as well as cytokines associated with activated mac-
rophages/microglia (IL-1a, IL-1b, IL-12p40, and TNF-a).
IFN-g and TNF-a have been shown to increase MHC
class I and/or class II molecules on a variety of cells (36–39),
and thus the presence of these cytokines may account for
Table 2. Activation of LCMV-Memory CTL by Infection with a Second Virus not Encoding LCMV Gene Products
Effectors
Targets
BALB (H-2d)
Uninf LCMV VV–NP VV Pichinde
BALB/c mice infected with
Single infection
LCMV ,3* 69 53 ,3 ,3
VV–NP ,33 3 6 6 4 6 , 3
VV ,3 ,36 1 5 5 , 3
Pichinde ,3 ,3 ,3N D 3 3
Double infection
1st virus 2nd virus
LCMV mock ,3 ,3N D N D N D
LCMV VV–NP ,36 6 6 0 2 9 N D
LCMV VV ,33 4 5 2 4 1 N D
LCMV Pichinde ,31 4 8 N D 1 1 ‡
* Values are the percentage of chromium released from MC57 or BALB target cells, with an effector/target ratio of 50:1. Doubly infected BALB/c
mice were first infected with LCMV, then 6 wk later were infected with a second virus as indicated; at day 7 (VV–NP and VV) or day 5 (Pichinde)
after second infection splenic lymphocytes were harvested for assay. The data shown are the averages of values from 2–4 mice per group.
‡These mice were killed at day 5 after second infection; peak anti-Pichinde CTL activity is at day 7.2381 Evans et al.
the widespread upregulation of MHC class I and II mole-
cules observed after double infection. In addition, TNF-a
and TNF-b have been shown to be cytotoxic to oligoden-
drocytes in vitro (40, 41). Damage to oligodendrocytes was
demonstrated by confocal microscopic analyses of the le-
sions of infiltrating lymphocytes within the white matter. A
number of observations were consistent with active myelin
degradation, including the loss of MBP staining at the cen-
ter of these lesions, the irregular shape of the lesions, the
presence of activated microglia/macrophages in and around
the lesions, and the uptake of MBP by these activated mi-
croglia/macrophages.
The enhanced disease observed after a second LCMV in-
fection shares several characteristics with the human CNS
disease, MS, including chronic perivascular and parenchy-
mal infiltration of autoreactive T cells in the brain and spi-
nal cord, lesions in myelin tracts associated with the uptake
of myelin components by activated macrophages/micro-
glia, upregulation of MHC class I and class II molecules on
resident CNS cells, activation of microglia and astrocytes,
motor coordination dysfunction, and expression of cyto-
kines in the CNS associated with cytotoxicity. MS is fur-
ther characterized by the presence of plaques of demyelination
in the CNS. These mice showed focal areas of demyelina-
tion consistent with sites of early plaque development. It is
possible that additional environmental or genetic factors could
influence further plaque development. Currently, studies
are being done to manipulate the susceptibility of these
mice to demyelination by evaluating the effects of genetic
background, CNS cytokine expression, and TCR usage.
Viruses have often been implicated in the etiology of MS
(42, 43), but it has not been possible to link just one virus
with the disease. This model provides an opportunity to
examine the roles of multiple viruses in inducing and po-
tentiating CNS demyelinating disease, and will comple-
ment results from studies of the classical model of autoim-
munity in MS, experimental allergic encephalomyelitis.
Primary infection of transgenic mice with LCMV led to
CNS infiltration by CD81 and CD41 T cells, at a ratio of
z5:1. This was not surprising, because the primary T cell
response to LCMV is mediated by CD81 cells (13, 14). How-
ever, no obvious damage to oligodendrocytes was observed
after a single LCMV infection of transgenic mice. After a
second viral infection of the transgenic mice, the propor-
tion of CD41 T cells increased relative to the number of
CD81 T cells (CD81/CD41, 2:1). Focal areas of myelin
degradation were observed (Fig. 4), and expression of both
MHC class I and class II molecules was found on oligoden-
drocytes (Horwitz, M.S., C.F. Evans, and M.B.A. Old-
stone, manuscript submitted for publication). These find-
ings suggest that CD81 and/or CD41 T cells may interact
directly with oligodendrocytes and play a role in oligoden-
drocyte injury. In addition, the total number of infiltrating
T cells in the CNS increased three- to fivefold after a sec-
ond infection with LCMV. Other models of autoimmune
diseases have shown that the number of self-reactive T cells
influences the development of disease (44–46), so it is pos-
sible that the myelin damage seen after a second LCMV in-
fection was a result of the increased numbers of infiltrating
T cells.
Two models of virus-induced insulin dependent diabetes
mellitus (19, 47) used the rat insulin promoter to direct
expression of the LCMV NP or GP to the b cells in the is-
lets of Langerhans of the pancreas. Upon infection with
LCMV, immune-mediated destruction of the b cells oc-
curred, resulting in diabetes. Although the transgenes and
the infecting virus are the same in the pancreatic and the
CNS models, destruction of the transgene-expressing target
cells was much more severe in the diabetic model. The pri-
mary difference between these models is the organ in
which the transgene is expressed. The CNS is unique due
to the blood–brain barrier, which restricts the entry of cer-
tain cells and molecules from the blood, and the low or
nondetectable expression of both MHC class I and class II
molecules. It is likely that the nature of the immune re-
sponse in the target organs is influenced by several factors,
including differences in permeability of the islet capillaries
and blood–brain barrier to various immune cells, in expres-
sion of adhesion and MHC molecules on endothelial and
target cells, in types of antigen-presenting cells present, and
in the local cytokine milieu. Delineation of the factors that
determine the outcome of the transgene-specific immune
response should reveal important differences between au-
toimmune disease of a peripheral organ such as the pan-
creas, and the CNS.
Intriguingly, the chronic CNS inflammatory disease in-
duced by a single LCMV infection was enhanced by sec-
ond infection with a virus other than LCMV. Infection of
naive transgenic mice with a virus not encoding LCMV
gene products did not lead to CNS autoimmune disease.
Exacerbation of CNS disease after infection with an unre-
lated virus required the presence of self-reactive (LCMV
transgene-specific) memory lymphocytes established by a
prior infection with LCMV. Studies of MBP-specific TCR
transgenic mice showed that mice housed in a nonsterile
environment spontaneously developed experimental aller-
gic encephalomyelitis (48). These observations suggested
that both the TCR repertoire and exposure to environ-
mental agents influenced susceptibility to CNS autoim-
mune disease. The results from our model indicate that the
potential of the TCR repertoire to respond to a self-anti-
gen, as well as the history of viral infections, are both cru-
cial to the development of autoimmune disease.
The enhanced pathology seen after a second infection
with a virus not encoding LCMV gene products is likely
due to activation of LCMV-specific memory CTL (Table
2). This could be due to a general nonspecific stimulation
of memory cells (bystander activation) after the upregula-
tion of cytokine expression in response to the second viral
infection (49). Preliminary experiments have shown that
treatment of LCMV-immune MBP–NP mice with the in-
terferon-inducer poly I/C (50, 51) did not result in en-
hanced CNS pathology. Alternatively, reactivation may be
a result of cross-reactivities of LCMV-specific CTL with
heterologous viral peptides presented by MHC class I mol-
ecules (33, 52). Experiments to distinguish between these2382 Virus-induced Central Nervous System Autoimmune Disease
possibilities are in progress. After poliovirus immunization
of human adults previously vaccinated for polio in child-
hood, immune responses to unrelated antigens (reovirus
and tetanus toxoid) were observed, indicating that second-
ary activation of immune responses also occurs in humans
(53). The cross-activation of memory T cells specific for an
oligodendrocyte protein by subsequent viral infections may
explain why patients with an autoimmune disease such as
MS often exhibit disease exacerbations after infections by
different viruses (54–56). It may also serve to explain both
the long lag period before disease symptoms and the risk
factor association of disease to the first 15 yr of life (57). A
cross-reactive immune response to oligodendrocyte-spe-
cific antigens through a process of molecular mimicry early
in life could lead to the generation of memory T cells spe-
cific for a myelin antigen. These self-reactive T cells could
then be reactivated after subsequent pathogen exposures,
eventually leading to clinically observable disease exacerba-
tions. Exploitation of the model described here will be use-
ful for evaluating the potential of unrelated viruses to con-
tribute to the exacerbation of CNS autoimmune disease,
and for developing therapies to modify such disease.
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